Protein / target

Myosin-7

MYH7P12883Homo sapiensSwiss-Prot
UniProt: P12883Ensembl: ENSG00000092054HGNC: HGNC:7577NCBI Gene: 4625
Clinically validated
Therapeutic maturity
2
Approved medicines
10
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Microfilament motor activity

Primary system

Musculoskeletal system

Strongest disease association

hypertrophic cardiomyopathy

Genetic evidence · score 0.97

Therapeutic maturity

Clinically validated target

2 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

2 approved · 1 in clinical development

10 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle

Subcellular location

Cytoplasm, myofibrilCytoplasm, myofibril, sarcomere
Domains and Gene Ontology detail (28)

Domains & features

Myosin N-terminal SH3-likeMyosin motorIQ

Gene Ontology

  • Ccytoplasm
  • Cmuscle myosin complex
  • Cmyofibril
  • Cmyosin complex
  • Cmyosin filament
  • Cmyosin II complex
  • Csarcomere
  • Cstress fiber
  • CZ disc
  • Factin filament binding
  • FATP binding
  • Fcalmodulin binding

1935 aa · 223 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Muscle contractionUniProt · GOMetabolic enzyme activityGO
View supporting evidence

Muscle contraction

  • ·Myosins are actin-based motor molecules with ATPase activity essential for muscle contra…
  • ·Cytoplasm, myofibril, sarcomere
  • ·muscle myosin complex
  • ·myosin complex

Metabolic enzyme activity

  • ·ATP metabolic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

MYL3ACTC1MYL2MYL1MYBPC3MYH6TPM1MYLPFTNNI1ACTN2MYH7

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

omecamtiv mecarbil
ApprovedActivator

Cardiac myosin activator

Appears in clinical studies involving cardiovascular disorder, heart failure, heart failure, Stroke

Acts on a complex — shared with MYH6, MYH7B, MYL3 +3 more · 1 of 7 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

hypertrophic cardiomyopathy0.97

Genetic · overall 0.89

hypertrophic cardiomyopathy 10.95

Genetic · overall 0.76

dilated cardiomyopathy0.94

Genetic · overall 0.72

cardiomyopathy0.91

Genetic · overall 0.76

left ventricular noncompaction0.89

Genetic literature · overall 0.79

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

congenital myopathy 7A, myosin storage, autosomal dominant0.80

Genetic

MYH7-related skeletal myopathy0.78

Genetic literature

familial isolated dilated cardiomyopathy0.71

Genetic literature

myopathy, myosin storage, autosomal recessive0.71

Genetic

Laing early-onset distal myopathy0.71

Genetic literature

Show all associations
hypertrophic cardiomyopathy0.89
congenital myopathy 7A, myosin storage, autosomal dominant0.80
left ventricular noncompaction0.79
MYH7-related skeletal myopathy0.78
hypertrophic cardiomyopathy 10.76
cardiomyopathy0.76
dilated cardiomyopathy0.72
familial isolated dilated cardiomyopathy0.71
myopathy, myosin storage, autosomal recessive0.71
Laing early-onset distal myopathy0.71

Open Targets ranks 437 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 3 total

DANICAMTIVPhase 2 3

dilated cardiomyopathy · heart failure · heart failure

OMECAMTIV MECARBILApproval

cardiovascular disorder · heart failure · heart failure

MAVACAMTENApproval

hypertrophic cardiomyopathy · cardiovascular disorder · hypertrophic cardiomyopathy

Tractability

SM · Approved DrugSM · Structure with LigandPR · Database Ubiquitination

Clinical trials

10

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HFPHASE3

WITHDRAWN · via omecamtiv mecarbil · NCT04464525

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailurePHASE2

COMPLETED · via omecamtiv mecarbil · NCT01300013

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT04175808

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT02601001

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)PHASE3

RECRUITING · via omecamtiv mecarbil · NCT06736574

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise TolerancePHASE3

COMPLETED · via omecamtiv mecarbil · NCT03759392

Show remaining trials (4)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionPHASE2

COMPLETED · via omecamtiv mecarbil · NCT02695420

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)PHASE3

COMPLETED · via omecamtiv mecarbil · NCT02929329

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart FailurePHASE2

WITHDRAWN · via omecamtiv mecarbil · NCT01077167

A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy VolunteersPHASE1

COMPLETED · via omecamtiv mecarbil · NCT01380223

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

hypertrophic cardiomyopathyWell supported
0.99
agreement 0.90–1.00
Genetic51%Clinical38%Animal model10%Literature2%Genetic literaturedup

Open Targets aggregate 0.89 · 4 independent evidence families · 1 not counted as duplicate

dilated cardiomyopathyWell supported
0.98
agreement 0.89–1.00
Genetic52%Somatic mutation22%Clinical15%Animal model10%Literature2%Genetic literaturedup

Open Targets aggregate 0.72 · 5 independent evidence families · 1 not counted as duplicate

hypertrophic cardiomyopathy 1Well supported
0.95
agreement 0.83–1.00
Genetic88%Animal model12%Genetic literaturedup

Open Targets aggregate 0.76 · 2 independent evidence families · 1 not counted as duplicate

cardiomyopathyWell supported
0.92
agreement 0.78–1.00
Genetic92%Literature8%

Open Targets aggregate 0.76 · 2 independent evidence families

left ventricular noncompactionWell supported
0.90
agreement 0.78–1.00
Genetic79%Animal model16%Literature4%Genetic literaturedup

Open Targets aggregate 0.79 · 3 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

1

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. New publication2020-11-13
    Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

    The New England journal of medicine · 2021 · 443 citations · Europe PMC · via omecamtiv mecarbil

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.